2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes.
Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the role of age and gender in advanced renal cell carcinoma (RCC) outcomes.
A growing body of evidence suggests that age and gender play a role in patient outcomes in RCC, says McKay.
This could be due to biologic differences in genetic profiles between men and women or younger and older patients, McKay explains.
Pharmacokinetic differences among patients with different genders, ages, and, perhaps, ethnicities may also influence outcomes as the presence of enzymes could result in differences in drug metabolism, says McKay.
Furthermore, toxicity patterns also tend to vary among younger and older patients, McKay concludes.
Related Content: